Conversely, the preliminary results from the phase III trial IPATunity showed that ipasertinib in combination with paclitaxel failed to improve outcomes in terms of PFS and of objective response rate (ORR) in PIK3/AKT1/PTEN-altered ER positive BC, missing the primary and secondary endpoints of the study [52]. This evidence concerns the gene PTEN and breast cancer.